ZINC ASPARTATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C4H5NO4.Zn.2H
Molecular Weight	329.598
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

[H+].[H+].[Zn++].N[C@@H](CC([O-])=O)C([O-])=O.N[C@@H](CC([O-])=O)C([O-])=O

InChI

InChIKey=POEVDIARYKIEGF-CEOVSRFSSA-L

InChI=1S/2C4H7NO4.Zn/c2*5-2(4(8)9)1-3(6)7;/h2*2H,1,5H2,(H,6,7)(H,8,9);/q;;+2/p-2/t2*2-;/m00./s1

HIDE SMILES / InChI

Molecular Formula	H
Molecular Weight	1.0079
Charge	1
Count	MOL RATIO 2 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C4H5NO4
Molecular Weight	131.0868
Charge	-2
Count	MOL RATIO 2 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	Zn
Molecular Weight	65.409
Charge	2
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Zinc aspartate is an approved drug, used to treat zinc deficiency in humans. Zinc aspartate regulates the production of the growth hormone and sex hormones (it is necessary for the production of sperm cells and egg cells). It reduces the body’s susceptibility to infections and allergies. It promotes the proper secretion of insulin by the pancreas. Zinc deficiency causes: disorders in the functioning of the skin, the digestive system, the nervous system, the immunological system, and the skeletal system. Significant zinc deficiency can cause dwarfism and genital underdevelopment. Zinc aspartate suppresses experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis (MS), as well as effector T cell functions in vitro.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
T cell activation involved in immune response 1	Inhibitor 8,297

Conditions

Condition	Modality	Highest Phase	Product
Multiple sclerosis 104	Primary	Preclinical	Unknown
Myringosclerosis 1	Preventing	Preclinical	Unknown
Ischemia-reperfusion injury 7	Primary	Preclinical	Unknown
Zinc deficiency 39	Primary	Approved 8,429	Zincas
Acrodermatitis enteropathica 1	Palliative	Preclinical	Unknown

PubMed

Show entries

Title	Date	PubMed
Oral zinc aspartate treats experimental autoimmune encephalomyelitis.	2014 Dec	25146336
Zinc and propolis reduces cytotoxicity and proliferation in skin fibroblast cell culture: total polyphenol content and antioxidant capacity of propolis.	2014 Jul	24913100
Congenital diseases of the gastrointestinal tract.	2014 May	24940857

Showing 1 to 3 of 3 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

For inflammatory bowel disease, 300 milligrams of zinc aspartate (equal to 60 milligrams of elemental zinc) has been taken by mouth daily for four weeks.

Route of Administration: Oral

In Vitro Use Guide

Zinc aspartate, at a concentration of 16 uM, increased human fibroblasts proliferation in cell culture